HCPCS Level II · Drugs administered other than oral method
J1413Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1413
J1413 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, delandistrogene moxeparvovec-rokl, per therapeutic dose.
It was added to HCPCS effective 01/01/2024.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj delandistrogene mox rokl
- Date added
- 01/01/2024
- Action effective
- 01/01/2024
- BETOS
- O1E
Related J14xx codes
- J1410Injection, estrogen conjugated, per 25 mg
- J1411Injection, etranacogene dezaparvovec-drlb, per therapeutic dose
- J1412Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector genomes
- J1414Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
- J1426Injection, casimersen, 10 mg
- J1427Injection, viltolarsen, 10 mg
- J1428Injection, eteplirsen, 10 mg
- J1429Injection, golodirsen, 10 mg
- J1430Injection, ethanolamine oleate, 100 mg
- J1434Injection, fosaprepitant (focinvez), 1 mg
- J1435Injection, estrone, per 1 mg
- J1436Injection, etidronate disodium, per 300 mg
Common questions about J1413
Is HCPCS J1413 still valid?
- Yes. J1413 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J1413?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.